Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx Eyes $1.5M Financing Round for Clinical Trials of Nucleosome-based Tests

NEW YORK (GenomeWeb News) – Cancer diagnostics firm VolitionRx has raised $595,000 toward a targeted $1.5 million round, it said in a document filed with the US Securities and Exchange Commission.

In an e-mail to GenomeWeb Daily News, a company spokesperson said the funding will go toward ongoing trials for its NuQ technology, including clinical trials announced late last month with Hvidovre Hospital in Denmark for colorectal cancer.

Investors in the round consisted of individual investors. The company has raised a total of $1.5 million in 2013 and about $6.0 million since its founding in late 2010.

In May 2012, the Singapore-based firm raised $1.2 million to fund clinical trials for its first NuQ test kits, which are blood-based diagnostic tests based on VolitionRx’s Nucleosomics technology. The technology detects and measures nucleosomes in the bloodstream.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.